



## Alfasigma Group Redeploys CARNITENE® (L-carnitine) Business in the Chinese Market

SHANGAI, AUGUST 2022 –

CARNITENE®<sup>1</sup> (L-carnitine), the blockbuster product of Alfasigma Group, was approved for marketing in China in the early 21<sup>st</sup> century. According to the report from IQVIA, the overall value of carnitine in China's hospital market was 2.168 billion RMB in 2021, of which CARNITENE® accounted for 38.3% market share. On June 30, 2022, the distribution license for CARNITENE® (L-carnitine) obtained in China by Lee's Pharmaceutical (HK) Limited officially expired. Since July 1, the right to distribute the product in China has been held by Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (hereafter referred to as Kyuan Trade). And starting from October 1, 2022, the promotional right of CARNITENE® in the Chinese market will return to Alfasigma China team.

Mrs. XU Ying, General Manager of Alfasigma (Shanghai) Medicine Consulting Co., Ltd. [hereinafter referred to as Alfasigma (Shanghai)], a new subsidiary of Alfasigma Group, presents the ceremony of CARNITENE® (L-carnitine) distribution cooperation meeting with Kyuan Trade on August 18, 2022, to further strengthen the long-standing strategic partnership previously established on the basis of granting an exclusive distributorship of Vessel Due F® capsules and XIFAXAN®. Mr. CHU Chenxi, General Manager of Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd., believes that under the in-depth cooperation with Alfasigma, CARNITENE® (L-carnitine) can further maximize its influence in the Chinese market and improve the quality of life of Chinese patients.

CARNITENE® (L-carnitine) is indicated for the treatment of carnitine deficiencies. In particular, CARNITENE® (L-carnitine) 1G/5ml and 2G/5ml injection is indicated for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. CARNITENE® (L-carnitine) 1G/10ml and 2G/10ml Oral Solution is indicated for the treatment of primary and secondary carnitine deficiency and for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.

---

<sup>1</sup> The information relating to Carnitene® and its use included in the text are exclusively informative, with a purely indicative purpose. None of such information should be interpreted as a substitute of medical advice and/or evaluations of an expert, for which it is necessary to consult a medical doctor or specialist and perform specific exams and checks. More information on the use of Carnitene® is provided with the products.

CARNITENE® is promoted to different specialist: **nephrologists** for the prevention and treatment of carnitine deficiency in patients undergoing Hemodialysis; **pediatricians** for the treatment of patients with an inborn error of metabolism, and to **Gynecologists, Urologists** and **Embryologists** for the treatment of Male Infertility.

Mrs. XU Ying, General Manager Alfasigma China, believes that CARNITENE® (L-carnitine) exhibits its never fading charms as time goes by and the Alfasigma China team will present the product with greater vitality and add a different color to it.

## Two major companies in a large market

**Alfasigma** is one of the top five Italian owned pharmaceutical companies and is broadly represented on the international market with a network of distributors that guarantee its diffusion throughout all five continents and in nearly 90 countries worldwide. Alfasigma's turnover in 2021 was over 1.030 billion euros.

Alfasigma entered the Chinese market in the late 90s, established Alfasigma (Beijing) Medicine Consulting Co., Ltd., its first wholly-owned subsidiary in China in 2004, and set up a branch in Shanghai in 2015. With the further expansion of its business in China, the second wholly-owned subsidiary of Alfasigma Group, Alfasigma (Shanghai) Medicine Consulting Co., Ltd. was founded in Shanghai in June 2022. With rapid development and growth, the Chinese market has ranked among the top five global markets for Alfasigma in terms of performance contribution.

Alfasigma (China) continuously introduce the latest patented original drugs onto the Chinese market, with a series of products including Vessel Due F®, XIFAXAN®, NEOTON®, FLUXUM® and Carnitene® marketed and widely used in clinical practice.

Alfasigma will, as always, commit to promoting development of China's medical field, enabling Chinese patients to benefit from medical, biotechnological and genetic engineering advances, and making contributions to China's medical industry.

**Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd.** is a core pharmaceutical import and distribution enterprise of Shanghai Pharmaceutical Science Park affiliated to Shanghai Pharmaceutical Group. It settled in Beijing Tianzhu Comprehensive Bonded Zone in 2009. It integrates import bonded, pharmaceutical circulation, vaccine services, digital marketing, market access Supply chain extension services and other diversified large-scale comprehensive service-oriented pharmaceutical enterprises, with business areas covering the whole country, had an operating revenue of 20.81 billion yuan in 2021, and the annual growth rate continued to exceed the industry average. The company is committed to becoming the best commercial enterprise in product distribution, supplier cooperation and customer service in the field of pharmaceutical circulation.



## Media Contacts

Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd.  
CAI Tianfu  
E-mail: [caitianfu@keyuanmed.com](mailto:caitianfu@keyuanmed.com)

Alfasigma S.p.A  
Corporate Communication & Media Relations Team  
E-mail: [CorporateCommunication@alfasigma.com](mailto:CorporateCommunication@alfasigma.com)